Breakthrough medicines during the COVID-19 pandemic era is a research paper published in Future Drug Discovery (2022). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Cancer Prevention and Research Institute of Texas
Grant: RP210180
National Institutes of Health
Grant: GM139727; CA210192; CA206069; CA204552
NCI NIH HHS
Grant: R01 CA206069
NCI NIH HHS
Grant: R01 CA210192
NIGMS NIH HHS
Grant: SC1 GM139727
NCI NIH HHS
Grant: R01 CA204552
National Institutes of Health
Grant: 7R01CA210192-05
Targeted Nanotherapy for Pancreatic Cancer
National Institutes of Health
Grant: 1R01CA206069-01A1
Development of Targeted Nanotechnology Platform for Pancreatic Cancer
National Institutes of Health
Grant: 5R01CA204552-03
MUC13 Mucin in Colorectal Cancer Health Disparity
National Institutes of Health
Grant: 5SC1GM139727-02
miR-205 Nanoparticle system circumvents docetaxel resistance in prostate cancer
FWCI
0.00
Citation Percentile
0.0%
Fields of Study
Keywords
Sustainable Development Goals